Catechol-O-Methyltransferase Polymorphism Is Not Associated with Ovarian Cancer Risk
A valine-108-methionine polymorphism in exon 4 of the catechol- O -methyltransferase ( COMT ) gene causes a 3- to 4-fold reduction in enzyme activity and has been associated with an increased risk of breast cancer. This increased risk may be attributable to a decreased ability of the protein encoded...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2000-12, Vol.9 (12), p.1373-1376 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1376 |
|---|---|
| container_issue | 12 |
| container_start_page | 1373 |
| container_title | Cancer epidemiology, biomarkers & prevention |
| container_volume | 9 |
| creator | GOODMAN, Julie E LAVIGNE, Jackie A HENGSTLER, Jan G TANNER, Berno HELZLSOUER, Kathy J YAGER, James D |
| description | A
valine-108-methionine polymorphism in exon 4 of the
catechol- O -methyltransferase
( COMT ) gene causes a 3- to 4-fold reduction in enzyme
activity and has been associated with an increased risk of breast
cancer. This increased risk may be attributable to a decreased ability
of the protein encoded by the low-activity allele
( COMT L ) to methylate and inactivate
catechol estrogens, which have been implicated in estrogen
carcinogenesis. Because estrogens have also been implicated in the
etiology of ovarian cancer, we analyzed 108 cases and 106 controls from
a case-control study conducted in Mainz, Germany, to test the
hypothesis that COMT L is associated with
ovarian cancer risk. No significant association was found between the
COMT genotype and ovarian cancer risk (for the
intermediate-activity COMT genotype
versus the high-activity COMT genotype, OR,
1.29; 95% CI, 0.63–2.64; for the low-activity COMT
genotype versus the high-activity COMT
genotype, OR, 1.17; 95% CI, 0.52–2.61). We also
hypothesized that women who were both low-activity COMT genotype- and glutathione
S-transferase ( GST ) M1- and/or
T1 null would be at higher risk for ovarian cancer
because the combination of these genotypes could theoretically lead to
higher catechol estrogen exposure. However, the association between the
COMT polymorphism and ovarian cancer risk was similar
across GSTM1 and GSTT1 genotypes
( P trend > 0.40, for all strata).
Because of the small sample size of this study population, odds ratios
of a small magnitude could not be completely ruled out; however, the
results presented do not support a strong association between the
COMT polymorphism and the risk of ovarian cancer. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_11142424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11142424</sourcerecordid><originalsourceid>FETCH-LOGICAL-h268t-6f33039ee117d9d78df577562629f238cec8c0fcf40e44883580c9c3120eda4f3</originalsourceid><addsrcrecordid>eNo9j01LAzEQhoMoVqt_QQJevATysdlNjmXxo1CtSD0vMTsx0d1uSVZL_73BVpnDzOGZl_c5QmdMCkWqSsrjfFMpidalnKDzlD4opZWW8hRNGGMFz3OGVrUZwfqhI0vyCKPfdWM06-QgmgT4eeh2_RA3PqQezxN-GkY8S2mwIX-1eBtGj5ffJgazxrVZW4j4JaTPC3TiTJfg8rCn6PXudlU_kMXyfl7PFsTzUo2kdEJQoQEYq1rdVqp1Mjcvecm140JZsMpSZ11BoSiUElJRq61gnEJrCiem6Gqfu_l666FtNjH0Ju6aP70MXB8Ak6zpXFazIf1zSvJSqEzd7Ckf3v02RGjsr0uEBCZa3-iG8YaJSogffH1nWw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Catechol-O-Methyltransferase Polymorphism Is Not Associated with Ovarian Cancer Risk</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>GOODMAN, Julie E ; LAVIGNE, Jackie A ; HENGSTLER, Jan G ; TANNER, Berno ; HELZLSOUER, Kathy J ; YAGER, James D</creator><creatorcontrib>GOODMAN, Julie E ; LAVIGNE, Jackie A ; HENGSTLER, Jan G ; TANNER, Berno ; HELZLSOUER, Kathy J ; YAGER, James D</creatorcontrib><description>A
valine-108-methionine polymorphism in exon 4 of the
catechol- O -methyltransferase
( COMT ) gene causes a 3- to 4-fold reduction in enzyme
activity and has been associated with an increased risk of breast
cancer. This increased risk may be attributable to a decreased ability
of the protein encoded by the low-activity allele
( COMT L ) to methylate and inactivate
catechol estrogens, which have been implicated in estrogen
carcinogenesis. Because estrogens have also been implicated in the
etiology of ovarian cancer, we analyzed 108 cases and 106 controls from
a case-control study conducted in Mainz, Germany, to test the
hypothesis that COMT L is associated with
ovarian cancer risk. No significant association was found between the
COMT genotype and ovarian cancer risk (for the
intermediate-activity COMT genotype
versus the high-activity COMT genotype, OR,
1.29; 95% CI, 0.63–2.64; for the low-activity COMT
genotype versus the high-activity COMT
genotype, OR, 1.17; 95% CI, 0.52–2.61). We also
hypothesized that women who were both low-activity COMT genotype- and glutathione
S-transferase ( GST ) M1- and/or
T1 null would be at higher risk for ovarian cancer
because the combination of these genotypes could theoretically lead to
higher catechol estrogen exposure. However, the association between the
COMT polymorphism and ovarian cancer risk was similar
across GSTM1 and GSTT1 genotypes
( P trend > 0.40, for all strata).
Because of the small sample size of this study population, odds ratios
of a small magnitude could not be completely ruled out; however, the
results presented do not support a strong association between the
COMT polymorphism and the risk of ovarian cancer.</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>PMID: 11142424</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Biological and medical sciences ; Case-Control Studies ; Catechol O-Methyltransferase - genetics ; Female ; Female genital diseases ; Genotype ; Glutathione Transferase - genetics ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Middle Aged ; Ovarian Neoplasms - enzymology ; Ovarian Neoplasms - genetics ; Polymorphism, Genetic ; Tumors</subject><ispartof>Cancer epidemiology, biomarkers & prevention, 2000-12, Vol.9 (12), p.1373-1376</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=852638$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11142424$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GOODMAN, Julie E</creatorcontrib><creatorcontrib>LAVIGNE, Jackie A</creatorcontrib><creatorcontrib>HENGSTLER, Jan G</creatorcontrib><creatorcontrib>TANNER, Berno</creatorcontrib><creatorcontrib>HELZLSOUER, Kathy J</creatorcontrib><creatorcontrib>YAGER, James D</creatorcontrib><title>Catechol-O-Methyltransferase Polymorphism Is Not Associated with Ovarian Cancer Risk</title><title>Cancer epidemiology, biomarkers & prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>A
valine-108-methionine polymorphism in exon 4 of the
catechol- O -methyltransferase
( COMT ) gene causes a 3- to 4-fold reduction in enzyme
activity and has been associated with an increased risk of breast
cancer. This increased risk may be attributable to a decreased ability
of the protein encoded by the low-activity allele
( COMT L ) to methylate and inactivate
catechol estrogens, which have been implicated in estrogen
carcinogenesis. Because estrogens have also been implicated in the
etiology of ovarian cancer, we analyzed 108 cases and 106 controls from
a case-control study conducted in Mainz, Germany, to test the
hypothesis that COMT L is associated with
ovarian cancer risk. No significant association was found between the
COMT genotype and ovarian cancer risk (for the
intermediate-activity COMT genotype
versus the high-activity COMT genotype, OR,
1.29; 95% CI, 0.63–2.64; for the low-activity COMT
genotype versus the high-activity COMT
genotype, OR, 1.17; 95% CI, 0.52–2.61). We also
hypothesized that women who were both low-activity COMT genotype- and glutathione
S-transferase ( GST ) M1- and/or
T1 null would be at higher risk for ovarian cancer
because the combination of these genotypes could theoretically lead to
higher catechol estrogen exposure. However, the association between the
COMT polymorphism and ovarian cancer risk was similar
across GSTM1 and GSTT1 genotypes
( P trend > 0.40, for all strata).
Because of the small sample size of this study population, odds ratios
of a small magnitude could not be completely ruled out; however, the
results presented do not support a strong association between the
COMT polymorphism and the risk of ovarian cancer.</description><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Catechol O-Methyltransferase - genetics</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Genotype</subject><subject>Glutathione Transferase - genetics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ovarian Neoplasms - enzymology</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Polymorphism, Genetic</subject><subject>Tumors</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j01LAzEQhoMoVqt_QQJevATysdlNjmXxo1CtSD0vMTsx0d1uSVZL_73BVpnDzOGZl_c5QmdMCkWqSsrjfFMpidalnKDzlD4opZWW8hRNGGMFz3OGVrUZwfqhI0vyCKPfdWM06-QgmgT4eeh2_RA3PqQezxN-GkY8S2mwIX-1eBtGj5ffJgazxrVZW4j4JaTPC3TiTJfg8rCn6PXudlU_kMXyfl7PFsTzUo2kdEJQoQEYq1rdVqp1Mjcvecm140JZsMpSZ11BoSiUElJRq61gnEJrCiem6Gqfu_l666FtNjH0Ju6aP70MXB8Ak6zpXFazIf1zSvJSqEzd7Ckf3v02RGjsr0uEBCZa3-iG8YaJSogffH1nWw</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>GOODMAN, Julie E</creator><creator>LAVIGNE, Jackie A</creator><creator>HENGSTLER, Jan G</creator><creator>TANNER, Berno</creator><creator>HELZLSOUER, Kathy J</creator><creator>YAGER, James D</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20001201</creationdate><title>Catechol-O-Methyltransferase Polymorphism Is Not Associated with Ovarian Cancer Risk</title><author>GOODMAN, Julie E ; LAVIGNE, Jackie A ; HENGSTLER, Jan G ; TANNER, Berno ; HELZLSOUER, Kathy J ; YAGER, James D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h268t-6f33039ee117d9d78df577562629f238cec8c0fcf40e44883580c9c3120eda4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Catechol O-Methyltransferase - genetics</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Genotype</topic><topic>Glutathione Transferase - genetics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ovarian Neoplasms - enzymology</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Polymorphism, Genetic</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GOODMAN, Julie E</creatorcontrib><creatorcontrib>LAVIGNE, Jackie A</creatorcontrib><creatorcontrib>HENGSTLER, Jan G</creatorcontrib><creatorcontrib>TANNER, Berno</creatorcontrib><creatorcontrib>HELZLSOUER, Kathy J</creatorcontrib><creatorcontrib>YAGER, James D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GOODMAN, Julie E</au><au>LAVIGNE, Jackie A</au><au>HENGSTLER, Jan G</au><au>TANNER, Berno</au><au>HELZLSOUER, Kathy J</au><au>YAGER, James D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Catechol-O-Methyltransferase Polymorphism Is Not Associated with Ovarian Cancer Risk</atitle><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>9</volume><issue>12</issue><spage>1373</spage><epage>1376</epage><pages>1373-1376</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><abstract>A
valine-108-methionine polymorphism in exon 4 of the
catechol- O -methyltransferase
( COMT ) gene causes a 3- to 4-fold reduction in enzyme
activity and has been associated with an increased risk of breast
cancer. This increased risk may be attributable to a decreased ability
of the protein encoded by the low-activity allele
( COMT L ) to methylate and inactivate
catechol estrogens, which have been implicated in estrogen
carcinogenesis. Because estrogens have also been implicated in the
etiology of ovarian cancer, we analyzed 108 cases and 106 controls from
a case-control study conducted in Mainz, Germany, to test the
hypothesis that COMT L is associated with
ovarian cancer risk. No significant association was found between the
COMT genotype and ovarian cancer risk (for the
intermediate-activity COMT genotype
versus the high-activity COMT genotype, OR,
1.29; 95% CI, 0.63–2.64; for the low-activity COMT
genotype versus the high-activity COMT
genotype, OR, 1.17; 95% CI, 0.52–2.61). We also
hypothesized that women who were both low-activity COMT genotype- and glutathione
S-transferase ( GST ) M1- and/or
T1 null would be at higher risk for ovarian cancer
because the combination of these genotypes could theoretically lead to
higher catechol estrogen exposure. However, the association between the
COMT polymorphism and ovarian cancer risk was similar
across GSTM1 and GSTT1 genotypes
( P trend > 0.40, for all strata).
Because of the small sample size of this study population, odds ratios
of a small magnitude could not be completely ruled out; however, the
results presented do not support a strong association between the
COMT polymorphism and the risk of ovarian cancer.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>11142424</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1055-9965 |
| ispartof | Cancer epidemiology, biomarkers & prevention, 2000-12, Vol.9 (12), p.1373-1376 |
| issn | 1055-9965 1538-7755 |
| language | eng |
| recordid | cdi_pubmed_primary_11142424 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research |
| subjects | Biological and medical sciences Case-Control Studies Catechol O-Methyltransferase - genetics Female Female genital diseases Genotype Glutathione Transferase - genetics Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Ovarian Neoplasms - enzymology Ovarian Neoplasms - genetics Polymorphism, Genetic Tumors |
| title | Catechol-O-Methyltransferase Polymorphism Is Not Associated with Ovarian Cancer Risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A26%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Catechol-O-Methyltransferase%20Polymorphism%20Is%20Not%20Associated%20with%20Ovarian%20Cancer%20Risk&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=GOODMAN,%20Julie%20E&rft.date=2000-12-01&rft.volume=9&rft.issue=12&rft.spage=1373&rft.epage=1376&rft.pages=1373-1376&rft.issn=1055-9965&rft.eissn=1538-7755&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E11142424%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11142424&rfr_iscdi=true |